Utilizing modern neuroscience drug development tools, Vigil Neuroscience rapidly delivers precision-based therapies to improve the lives of patients and families. The company is currently progressing its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, and advancing a small molecule TREM2 agonist to IND. Additionally, Vigil Neuroscience aims to grow its pipeline and gather more data to support microglia biology as a crucial therapeutic pathway.